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Abstract
Background: Lymph node status is the most important prognostic factor for colorectal cancer. The number of lymph 
nodes that should be histologically examined has been controversial. The aims of this study were to assess the impact 
of the number of lymph nodes examined on survival of patients with stage II colorectal cancer and to determine the 
optimal number of lymph nodes that should be examined.
Methods: The study included 664 patients who underwent resection for stage II colorectal cancer. The clinical and 
histopathologic data of the patients were prospectively collected and analyzed.
Results: The median number of lymph nodes examined was 12 (range: 1 to 58). The 5-year disease free survival rate 
was significantly higher for patients with 12 or more lymph nodes examined compared to those with less than 12 
lymph nodes examined. The significant difference in 5-year disease free survival persisted if the dividing number 
increased progressively from 12 to 23. However, the difference in survival was most significant (lowest p value and 
highest hazard ratio) for the number 21. The 5-year disease free survival of patients with 21 or more lymph nodes 
examined was 80% whereas that of patients with less than 21 lymph nodes examined was 60% (p = 0.001, hazard ratio 
2.08). Multivariate analysis showed that 21 or more lymph nodes examined was a factor that independently influenced 
survival. The 5-year disease free survival also increased progressively with the number of lymph node examined up to 
the number 21. After the number 21, the survival rate did not increase further. It was likely that 21 was the optimal 
number, at and above which the chance of lymph node metastasis was minimal.
Conclusions: The number of lymph nodes examined in colorectal cancer specimen significantly influences survival. It 
is recommended that at least 21 lymph nodes should be examined for accurate diagnosis of stage II colorectal cancer.
Background
Accurate assessment for the presence of lymph node
metastasis is critical in predicting the clinical outcome of
patients who have undergone radical surgery for colorec-
tal cancer. The status of the lymph nodes also largely
determines whether adjuvant chemotherapy should be
given; such adjuvant chemotherapy has been shown
unequivocally to provide disease-free as well as overall
survival benefits in patients with node positive disease
[1]. However, there is always a risk of disease understag-
ing if the extent of lymph nodes assessment is sub-opti-
mal. A tumor with lymph node involvement may be
incorrectly classified as stage I or II if the number of
lymph nodes examined is too small. The minimum num-
ber of lymph nodes that should be histologically exam-
ined for accurate staging of colorectal cancer has been
controversial. While current guideline from the Ameri-
can Joint Committee on Cancer patient recommends the
assessment of 12 lymph nodes or more [2], the recom-
mendations in the literature range from 6 to 18 nodes [3-
12]. The aims of this study were to assess the impact of
the number of lymph nodes examined on survival of
patients who underwent radical surgery for stage II col-
orectal cancer and to determine the optimal number of
lymph nodes that should be examined.
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The study is a retrospective review and the protocol of
'Evaluation of clinical and pathological factors affecting
outcomes following colorectal surgery' was approved by
the Institution Review Board of the hospital. Between
2000 and 2006, a total of 664 patients underwent radical
resection of colorectal cancer in the Department of Sur-
gery, Queen Mary Hospital, The University of Hong Kong
and their tumors were classified as stage II (T3-4N0M0)
according to the 6th edition of the TNM staging system of
the International Union Against Cancer [13]. The clinical
and histopathologic data of each patient were prospec-
tively collected and entered into a computer database.
The histopathologic features that were recorded included
depth of tumor invasion (T3 or T4), tumor type (adeno-
carcinoma or mucinous carcinoma), tumor grade (well,
moderately or poorly differentiated), lymphovascular
permeation and number of lymph nodes examined.
Concerning examination of the surgical specimens,
most of the specimens were fixed in 10% formalin and all
were routinely processed for paraffin embedding. Lymph
nodes in the specimen were identified by sight and palpa-
tion. Routine histopathologic examination was carried
out using hematoxylin and eosin staining. No special fat
clearance or staining techniques were routinely
employed.
Adjuvant chemotherapy was given to patients with risk
factors including emergency operation, mucinous carci-
noma, lymphovascular permeation and less than 12
lymph nodes examined. All the patients were regularly
followed up: every 3 months for the first 2 years, every 6
months for the following 3 years and then once a year.
The median follow-up period was 44 months (range 12 -
104 months). Serum carcinoembryonic antigen level was
measured regularly and imaging studies were performed
in situations where recurrences were suspected.
The relationship between various clinical and histologi-
cal variables and survival was evaluated using the Kaplan-
Meier method. Differences between survival curves were
tested for statistical significance by using log rank test.
The Cox proportional hazard regression model was
used to identify the variables that could indepen-
dently influence survival. Concerning the number of
lymph nodes examined, attempts were made to deter-
mine if there was a specific number at and above which
the chance of lymph node involvement was minimal.
Potential associations between the number of lymph
nodes examined and other variables were also evaluated.
Statistical Package for the Social Sciences, version 16.0
(SPSS Inc., Chicago, IL, USA) was used for all the statisti-
cal analysis. A p value of less than 0.05 was considered to
be statistically significant.
Results
Of the 664 patients included, 385 were men and 279
women. Their age ranged from 27 to 96 years with a
mean of 70 years. Location of tumors, urgency of opera-
tion (elective or emergency), depth of tumor invasion,
tumor type, tumor grade and lymphovascular permeation
were summarized in Table 1. The number of lymph nodes
examined in each specimen ranged from 1 to 58 with a
median of 12. The overall disease free survival of this
group of patients was shown in Figure 1. The 5-year dis-
ease free survival rates in relationship to different clinical
and histological variables were shown in Table 2. The 5-
year disease free survival rate was significantly higher in
patients underwent elective operation and in patients
Table 1: Clinical and Histopathologic Data of All Patients
Number of Patients
Location of tumors
Ascending colon 131
Transverse colon 81
Descending colon 49
Sigmoid 161
Rectosigmoid junction 50
Rectum 192
Urgency of operation
Elective 563
Emergency 101
Depth of tumor invasion
T3 585
T4 79
Tumor type
Adenocarcinoma 606
Mucinous carcinoma 58
Tumor grade
Well differentiated 40
Moderately differentiated 580
Poorly differentiated 44
Lymphovascular permeation
No 576
Yes 88
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lymphovascular permeation were associated with a sig-
nificantly lower survival rate.
The relationships between survival and different num-
ber of lymph nodes examined were evaluated. The 5-year
disease free survival rate was significantly higher for
patients with 12 or more lymph nodes examined com-
pared to those with less than 12 lymph nodes examined.
The significant difference in 5-year disease free survival
persisted if the dividing number increased progressively
from 12 to 23. However, the difference in survival was
most significant (lowest p value and highest hazard ratio)
for the number 21. (Table 3) The 5-year disease free sur-
vival rate of patients with 21 or more lymph nodes exam-
ined was 80% whereas that of patients with less than 21
lymph nodes examined was 60% (p = 0.001, hazard ratio
2.08). (Figure 2) The 5-year disease free survival also
increased progressively with the number of lymph node
examined up to the number 21. After the number 21, the
survival rate did not increase further. It was likely that 21
was the optimal number, at and above which the chance
of lymph node metastasis was minimal. (Table 3)
The variables including urgency of operation, depth of
tumor invasion, tumor type, lymphovascular permeation
and 21 or more lymph nodes examined were put into Cox
proportional hazard regression model. The results
showed that all the variables except tumor type were
independent factors that significantly influenced survival.
(Table 4)
The relationships between the number of lymph nodes
examined and the other clinical and histological variables
were shown in Table 5. Statistical analysis revealed that
no specific variable had significant association with the
number of lymph nodes examined. The number of lymph
nodes examined in colon cancer specimen was also not
statistically different from that of rectal cancer specimen
(12.9 vs. 11.3 p = 0.1).
Discussion
Lymph node involvement is the most important prognos-
tic factor after radical surgery for colorectal cancer
[14,15]. An accurate examination of the surgical speci-
men is mandatory to assess the lymph node status of the
tumor correctly. Ideally all the lymph nodes should be
harvested from the surgical specimen and examined in
order to confirm that a tumor is node negative. At pres-
ent, however, this goal is not practical. The actual number
of lymph nodes that must be examined in the resected
specimen has not yet been determined definitely. In the
Figure 1 Disease free survival of all the 664 patients.
Table 2: 5-year Disease Free Survival Rates in Relationship 
to Different Clinical and Histopathologic Variables
5-year Disease
 Free Survival
p
Sex
Male 60% 0.103
Female 66%
Tumor Location
Proximal to splenic flexure 64% 0.364
Distal to splenic flexure 62%
Urgency of operation
Elective 65% 0.002
Emergency 50%
Depth of tumor invasion
T3 65% 0.000
T4 46%
Tumor type
Adenocarcinoma 70% 0.007
Mucinous carcinoma 61%
Tumor grade
Well or moderately 
differentiated
63% 0.438
Poorly differentiated 61%
Lymphovascular permeation
No 65% 0.000
Yes 45%
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universally valid minimum number of lymph nodes,
above which there is no risk of understaging. Scott et al
studied 50 cases of Dukes' C tumor and showed that 13
lymph nodes had to be examined to identify 94% of the
specimen containing nodal metastases [3]. In 1990, the
Working Party Report to the World Congress of Gastro-
enterology in Sydney recommended that a minimum of
12 lymph nodes should be examined [4]. Hernanz et al,
based on a group of patients with colorectal cancer in
which 75 were classified as Dukes' C, showed that if 6
lymph nodes were examined the probability to find at
least a positive lymph node was 95 percent. The probabil-
ity increased to 99 percent if 10 lymph nodes were exam-
ined. The authors concluded that 6 lymph nodes
provided an accurate assessment of the presence of nodal
metastasis and an optimal Dukes' B classification [5].
Goldstein et al and Maurel et al showed that the probabil-
ity of correctly classifying a colorectal tumor as node pos-
itive increased with the number of examined lymph
nodes. They also reported that this increase had a pla-
teau. In their two series of patients, this plateau was
reached when 17 lymph nodes in one and 16 in the other
had been examined [6,7]. Tepper et al divided patients
with stage II rectal cancer into four quartiles according to
the number of lymph nodes examined and suggested that
14 lymph nodes needed to be studied to define nodal sta-
tus accurately [8]. Cianchi et al found that the 5-year sur-
vival rate of stage II patients with eight or fewer lymph
nodes examined was similar to that of stage III patients.
Their results suggested that examining a minimum of
nine lymph nodes per surgical specimen might be suffi-
cient for reliable staging of lymph node negative tumors
[9]. Swanson et al classified patients with T3N0 colon
cancer into three groups according to the number of
Table 3: 5-year Disease Free Survival Rates in Relationship to Number of Lymph Nodes Examined
Number (N) 5-year disease free survival if 
lymph nodes examined < N
5-year disease free survival if 
lymph nodes examined ≥ N
P Value Hazard ratio 95% confidence 
interval
8 56% 65% 0.281 1.18 0.89 - 1.55
9 57% 65% 0.322 1.14 0.86 - 1.49
10 56% 66% 0.055 1.29 0.99 - 1.69
11 58% 67% 0.074 1.26 0.97 - 1.64
12 57% 70% 0.015 1.39 1.06 - 1.82
13 57% 70% 0.006 1.46 1.11 - 1.93
14 57% 71% 0.005 1.49 1.12 - 1.98
15 59% 71% 0.011 1.46 1.08 - 1.97
16 59% 73% 0.004 1.61 1.67 - 2.22
17 59% 75% 0.003 1.72 1.21 - 2.44
18 59% 77% 0.003 1.93 1.31 - 2.84
19 59% 78% 0.002 1.99 1.32 - 2.99
20 59% 79% 0.002 2.05 1.33 - 3.16
21 60% 80% 0.001 2.08 1.36 - 3.33
22 60% 79% 0.006 1.92 1.19 - 3.12
23 61% 75% 0.045 1.64 1.00 - 2.69
24 61% 75% 0.058 1.71 0.99 - 2.93
25 61% 74% 0.085 1.65 0.92 - 2.95
Figure 2 Disease free survival of patients with at least 21 and less 
than 21 lymph nodes examined.
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lymph nodes should be examined to label the cancer as
node negative [10]. Tsai et al reviewed a group of patients
with T2-4N0M0 colorectal cancer and suggested that
examining a minimum of 18 lymph nodes per surgical
specimen might be taken into consideration for more
reliable staging of lymph node negative cancer [11].
Vather et al analyzed various lymph node strata and
showed a sharp and statistically significant drop in recur-
rence rate after the 16th node mark. The recurrence rate
remained at a low level for the remaining strata [12]. In
our study, we demonstrated that the number of lymph
nodes examined significantly influenced survival and the
difference in survival was most significant when compar-
Table 4: Multivariate Analysis of Variables Showing Significant Association with Disease Free Survival
Hazard Ratio 95% Confidence Interval p
Urgency of operation 1.68 1.20 - 2.36 0.0025
Depth of tumor invasion 1.84 1.30 - 2.60 0.0006
Tumor type 1.98 0.96 - 3.96 0.0617
Lymphovascular permeation 2.09 1.48 - 2.96 0.0001
Lymph nodes examined ≥ 21 2.08 1.36 - 3.33 0.0025
Table 5: Number of Lymph Nodes Examined in Relationship to Different Clinical and Histopathologic Variables
Number of lymph nodes P Value
Sex
Male 11.84 0.168
Female 12.70
Tumor Location
Proximal to splenic flexure 12.89 0.654
Distal to splenic flexure 12.34
Urgency of operation
Elective 12.08 0.379
Emergency 12.84
Depth of tumor invasion
T3 12.36 0.136
T4 10.93
Tumor type
Adenocarcinoma 12.04 0.082
Mucinous carcinoma 13.98
Tumor grade
Well or moderately differentiated 12.12 0.395
Poorly differentiated 13.10
Lymphovascular permeation
No 12.21 0.907
Yes 12.10
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less than 21 lymph nodes examined. Indeed, 21 or more
lymph nodes examined was an independent prognostic
factor associated with better disease free survival. We
also found that the 5-year disease free survival rate
increased progressively with the number of lymph node
examined up to the number 21. After the number 21, the
survival rate did not increase further. It was likely that 21
was the optimal number, at and above which the chance
of lymph node metastasis was minimal. We recommend
that a minimum of 21 lymph nodes should be examined
to label a tumor as node negative. The variability in
searching ability for lymph nodes by pathologists and the
different statistical methods employed are probably the
major factors that explain the considerable variation
among the different studies.
A proportion of patients in our study had adjuvant che-
motherapy administered. Ideally this group of patients
should be excluded when the survival rates were evalu-
ated. However, in our practice adjuvant chemotherapy
was only given to stage II patients with risk factors
including emergency operation, mucinous carcinoma,
lymphovascular permeation and less than 12 lymph
nodes examined. These factors were all shown to be asso-
ciated with lower survival rates. Therefore the inclusion
of patients treated with chemotherapy should not affect
the overall results.
The number of lymph nodes recovered from resection
specimens is dependent on several factors. The variability
in the number of lymph nodes in various regions of the
large bowel and the extent of surgical lymphadenectomy
alter the exact number of lymph nodes in a resection
specimen. The diligence and skill of the pathologist in
identifying and harvesting lymph nodes in the specimen
determine the actual number of lymph nodes examined.
It has been shown that nodal metastasis in colorectal can-
cer is often found in small lymph nodes (< 5 mm in diam-
eter) [16,17], diligent search for lymph nodes is required
on gross examination of resection specimens. Of note,
many pathologists are uninformed about the necessity of
examining a critical number of lymph nodes to accurately
stage colorectal cancers. One Canadian study showed
that only 58% of pathologists were aware of guidelines for
lymph node retrieval in colorectal cancer at all and that as
few as 25% knew that a minimum of 12 lymph nodes
(National Cancer Institute guidelines 2000) is necessary
for accurate designation of node negativity [18].
Lymph node collection from colorectal resection speci-
men is time consuming, particularly if the lymph nodes
are small. Small lymph nodes are difficult to be found,
especially amid large amount of mesenteric fat. Owing to
the lack of widely accepted pathology practice standards
for lymph node examination in colorectal cancer speci-
mens, there are many variations in the basic pathologic
techniques used for lymph node collection and submis-
sion for microscopic analysis. Some of these variations
include the use of clearing solutions to improve visualiza-
tion of small lymph nodes in the pericolonic or perirectal
fat, the submission of one half versus both halves of each
node for microscopic examination, and the preparation of
one versus more than one tissue level per paraffin block
of submitted nodal tissue. In an effort to reduce this vari-
ation, the College of American Pathologists has recom-
mended that all grossly negative or equivocal lymph
nodes be submitted in their entirety for microscopic
examination. For grossly positive lymph nodes, it is rec-
ommended that a representative sample be submitted for
microscopic confirmation. However, if fewer than 12
lymph nodes are found after careful gross examination, it
is suggested that additional visual enhancement tech-
niques that aid in the macroscopic identification of lymph
node, such as fat clearing, be considered [3,19]. Unfortu-
nately, the purchase and disposal costs for chemicals
required for these techniques are high.
Hsu et al demonstrated that larger tumor, (tumor local-
ization) and (depth of tumor invasion) were associated
with a higher number (12 or more) of harvested lymph
nodes in colorectal cancer specimen [20]. On the other
hand, Horzic et al found that male gender, greater tumor
size, better tumor differentiation as well as presence of
acute inflammation in the abdominal cavity were inde-
pendent predictors of increased number of examined
lymph nodes [21]. According to the author, well-differen-
tiated tumors were associated with increased number of
examined lymph nodes. That might be due to better
immune response against better-differentiated tumors.
The association between acute inflammation in the
abdominal cavity and number of lymph nodes examined
might be explained by the fact that any inflammation
causes reactive hyperplasia of lymph nodes. In our study,
however, we could not identify any clinical or histological
factor that influenced the number of lymph nodes exam-
ined.
Instead of exhaustive lymph node harvest and examina-
tion, an alternative way to determine lymph node status is
sentinel lymph node biopsy. This approach has been
extensively used for breast cancer and melanoma. How-
ever, the value of sentinel lymph node biopsy for colorec-
tal cancer is still limited. A lot of studies have evaluated
the role of sentinel lymph node biopsy in the manage-
ment of colorectal cancer. At present sentinel lymph node
biopsy has not been shown to be a reliable predictor of
N0 status due to its relatively high false negative rate
[22,23]. Formal lymphadenectomy and intensive lymph
node examination are still essential for colorectal cancer.
Conclusions
In summary, the number of lymph nodes examined in
colorectal cancer specimen significantly influenced sur-
vival and the difference in survival was most significant
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and those with less than 21 lymph nodes examined.
Twenty one or more lymph nodes examined was an inde-
pendent prognostic factor associated with better disease
free survival. The chance of lymph node metastasis was
likely minimal if at least 21 lymph nodes showed no
tumor involvement. We thus recommend that a mini-
mum of 21 lymph nodes should be examined to label a
tumor as node negative. The diligence and skill of pathol-
ogists remains an important factor that determines the
actual number of lymph node examined. It is unlikely that
sentinel lymph node biopsy can substitute for intensive
lymph node examination in the management of colorec-
tal cancer.
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